Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012)*

A. Lejeune, Katherine A Skorupski, S. Frazier, I. Vanhaezebrouck, Robert B Rebhun, C. M. Reilly, C. O. Rodriguez

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - 2013

Fingerprint

mast cells
Mast Cells
drug therapy
Canidae
Dogs
Lomustine
vinblastine
prednisone
Drug Therapy
therapeutics
neoplasms
Vinblastine
dogs
Prednisone
metastasis
Survival
Neoplasms
surgery
Neoplasm Metastasis
radiotherapy

Keywords

  • Canine
  • Chemotherapy
  • Mast cell tumour
  • Radiation therapy
  • Surgery

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{53e95d7238204c8eb4740aceb5e9c15e,
title = "Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012)*",
abstract = "This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.",
keywords = "Canine, Chemotherapy, Mast cell tumour, Radiation therapy, Surgery",
author = "A. Lejeune and Skorupski, {Katherine A} and S. Frazier and I. Vanhaezebrouck and Rebhun, {Robert B} and Reilly, {C. M.} and Rodriguez, {C. O.}",
year = "2013",
doi = "10.1111/vco.12042",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour

T2 - 21 cases (1999-2012)*

AU - Lejeune, A.

AU - Skorupski, Katherine A

AU - Frazier, S.

AU - Vanhaezebrouck, I.

AU - Rebhun, Robert B

AU - Reilly, C. M.

AU - Rodriguez, C. O.

PY - 2013

Y1 - 2013

N2 - This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.

AB - This retrospective case series evaluates the outcome of 21 dogs with grade II stage 2 mast cell tumour (MCT) treated with adequate local therapy and adjuvant systemic chemotherapy (prednisone, vinblastine and CCNU). The median survival for all dogs was 1359days (range, 188-2340). Median disease-free interval was 2120days (149-2325days). Dogs treated with surgery and chemotherapy had shorter survival (median, 1103days; 188-2010days) than those that underwent surgery, radiation therapy and chemotherapy as part of their treatment (median, 2056days; 300-2340days). Two patients had local recurrence in the radiation field and four patients had de novo MCT. Distant metastasis was not observed in any dogs. The results of this study suggest that, in the presence of loco-regional lymph node metastasis in grade II MCT, the use of prednisone, vinblastine and CCNU after adequate local-regional therapy can provide a median survival in excess of 40months.

KW - Canine

KW - Chemotherapy

KW - Mast cell tumour

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84878310240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878310240&partnerID=8YFLogxK

U2 - 10.1111/vco.12042

DO - 10.1111/vco.12042

M3 - Article

C2 - 23721492

AN - SCOPUS:84939653326

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -